1. Provides responses to requests for records for the Public Health Service (PHS) or records involving more than one PHS component, including records relating to the PHS components located in the regions.

Dated: December 17, 1998.

Donna E. Shalala,

Secretary.

[FR Doc. 98–33922 Filed 12–22–98; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Comprehensive STD Prevention Systems (CSPS)—Enhanced Activities

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Comprehensive STD Prevention Systems (CSPS)—Enhanced Activities, Program Announcement #99000, meeting.

Times and Dates:

8:30 a.m.—9 a.m., January 13, 1999 (Open).

9 a.m.—4:30 p.m., January 13, 1999 (Closed).

9 a.m.—4:30 p.m., January 14, 1999 (Closed).

Place: National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, Building 11, Room 2214, Atlanta, Georgia 30329.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement #99000.

Contact Person for More Information: John R. Lehnherr, Chief, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 11 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639–8025.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: December 17, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.

[FR Doc. 98–33948 Filed 12–22–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98F–1166]

Occidental Chemical Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Occidental Chemical Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of sodium dichloroisocyanurate/sodium bromide as a slimicide for the manufacture of food-contact paper and paperboard.

FOR FURTHER INFORMATION CONTACT: Mark A. Hepp, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3098.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 8B4571) has been filed by Occidental Chemical Corp., c/o SRA International Inc., 1850 M St. NW., suite 290, Washington, DC 20036. The petition proposes to amend the food additive regulations in § 176.300 *Slimicides* (21 CFR 176.300) to provide for the safe use of sodium dichloroisocyanurate/sodium bromide as a slimicide for the manufacture of food-contact paper and paperboard.

The agency has determined under 21 CFR 25.32(q) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: December 7, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98–33917 Filed 12–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Cardiovascular and Renal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 28, 1999, 9 a.m. to 5:30 p.m. and January 29, 1999, 8:30 a.m. to 4:30 p.m.

Location: National Institutes of Health, Natcher Conference Center, 45 Center Dr., Bethesda, MD.

Contact Person: Joan C. Standaert, Center for Drug Evaluation and Research (HFD–110), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 419–259–6211, or John M. Treacy (HFD–21), 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12533. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 28, 1999, the committee will discuss new drug application (NDA) 20–931, Tikosyn™ Capsules (dofetilide), Pfizer Pharmaceuticals Production Corp., Ltd., for maintenance of normal sinus rhythm with associated symptomatic relief in patients with supraventricular arrhythmias, e.g., atrial flutter, atrial fibrillation, and paroxsysmal supraventricular tachycardia; and conversion of atrial fibrillation and flutter to normal sinus rhythm. On January 29, 1999, the committee will discuss NDA 20–920, Natrecor® Injection (nesiritide), Scios, Inc., for short term treatment of congestive heart failure.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 18, 1999. Oral presentations from the public will be scheduled between approximately 9 a.m. and 10 a.m. on January 28, 1999.